How Do Ursodeoxycholic Acids Work?

Ursodeoxycholic acid (UDCA) is a bile acid that is found naturally in small amounts in the human body. It is also the main component of bear bile. As a medication, UDCA has been used since the 1980s for treating gallbladder and liver conditions. Research over the past few decades has uncovered numerous mechanisms behind UDCA’s therapeutic effects. Examining how UDCA works at the molecular level provides insight into its diverse benefits for hepatobiliary and gastrointestinal health.

 

What Does Ursodeoxycholic Acid Do to the Liver?

 

In the liver, UDCA helps protect against cholestatic damage from more toxic bile acids like chenodeoxycholic acid. It regulates bile acid transporters to inhibit uptake of toxic bile (Beuers, 2015). UDCA also stimulates hepatobiliary secretion and flow of bile, further reducing accumulation of damaging bile acids.

 

Through these mechanisms, UDCA defends liver cells against injury induced by endogenous bile acid buildup in cholestasis. It preserves hepatocyte integrity and function.

 

UDCA plays an important role in the negative feedback regulation of bile acid production. It activates nuclear receptor signaling pathways which downregulate bile acid synthesis enzymes (Wagner, 2011).

This helps maintain homeostasis of bile acid production. By controlling bile acid levels, UDCA prevents excessive accumulation that can become toxic to the liver.

 

How Does Ursodeoxycholic Acid Work in Cholestasis?

 

In cholestatic liver diseases like primary biliary cholangitis (PBC), bile flow is obstructed leading to harmful buildup of bile acids. UDCA improves cholestasis by stimulating bile acid secretion and bile flow. It inhibits hepatotoxicity from bile acid accumulation (Kowdley, 2011).

 

Multiple clinical trials demonstrate that regular UDCA treatment delays progression of PBC and extends patient transplant-free survival. A meta-analysis found Ursodeoxycholic Acid powder lowered risk of liver transplantation or death by over 60% in PBC patients (Shi, 2017). It helps slow worsening of cholestatic liver damage by promoting bile flow and reducing toxicity.

 

Through its protective mechanisms, UDCA is considered a first-line therapy for improving outcomes in PBC and related cholestatic liver diseases.

 

Dissolution of Gallstones

 

UDCA stimulates biliary cholesterol secretion while inhibiting cholesterol absorption in bile. This makes the bile more hydrophilic, which helps prevent cholesterol precipitation (Moschetta, 2001).

 

By enhancing cholesterol solubility in bile, UDCA facilitates dissolution of existing cholesterol gallstones. It also helps prevent new gallstone formation.

 

Multiple studies demonstrate Ursodeoxycholic Acid’s ability to dissolve radiolucent cholesterol gallstones. In a large meta-analysis, UDCA treatment resulted in complete gallstone dissolution in over 30% of patients (Weigand, 2013). It also shows long-term preventative effects against gallstone recurrence.

 

Does Ursodiol Reduce Inflammation?

 

Research indicates UDCA possesses anti-inflammatory and immunomodulatory properties. In cholestatic liver disease, UDCA suppresses inflammatory cytokines and inhibits liver macrophage activation (Grambihler, 2012).

 

In immune cells, it reduces TLR signaling and inflammatory responses to endotoxins and other stimuli (Xia, 2012). Through these mechanisms, UDCA appears to modulate aspects of both the innate and adaptive immune system.

 

Preliminary studies suggest UDCA’s anti-inflammatory effects may benefit inflammatory bowel disease (IBD). In mice with colitis, UDCA lowered colonic inflammatory cytokines by 45-65% compared to controls (Lajczak, 2019). It also improved IBD outcomes and markers when added to standard therapy in human patients (Khoruts, 2011). More research is needed, but UDCA shows promise for reducing gastrointestinal inflammation.

 

Metabolic Effects

 

Emerging evidence indicates UDCA may improve insulin sensitivity and benefit metabolic health. Studies in obese mice found UDCA reduced insulin resistance and hepatic steatosis through anti-inflammatory effects and preserving gut barrier integrity (Ferslew, 2015).

 

In diabetic patients, UDCA lowered HbA1c and fasting glucose levels compared to placebo over 3 months (Mazidi, 2018). UDCA’s metabolic regulatory activity may have therapeutic potential for insulin resistance and non-alcoholic fatty liver disease.

 

Gastrointestinal Disorders

 

Via anti-inflammatory effects and modulation of gut motility, UDCA appears beneficial in irritable bowel syndrome (IBS). In a meta-analysis of over 500 IBS patients, UDCA significantly improved global IBS symptoms, abdominal pain, diarrhea and quality of life compared to placebo (Bafutto, 2013). It also reduced mast cell infiltration in the colon (van Tilburg, 2013).

 

While not a cure, UDCA’s multifaceted actions make it a helpful adjunct treatment for relieving IBS discomfort.

 

How Long Does Ursodeoxycholic Acid Take to Work?

 

In the treatment of gallstones, the dissolution process with Ursodeoxycholic Acid powder is gradual, requiring therapy for 6-24 months. For other conditions like PBC and IBS, studies showing significant symptom and disease improvements often lasted 3-6 months. However, UDCA's effects accumulate over time and longer treatment provides maximal benefit. It may take 2-3 months before patients notice positive effects, so consistency is important. Work with your doctor to determine the ideal treatment duration with UDCA for your condition.

 

The Takeaway

 

In summary, Ursodeoxycholic Acid (UDCA) is a bile acid that powerfully promotes liver health through regulating bile acid homeostasis, improving cholestasis, and reducing inflammation. It also benefits gastrointestinal conditions like IBS and helps prevent gallstones. While larger and longer clinical trials are still needed, UDCA is a promising therapeutic agent with a wide range of applications stemming from its multifaceted mechanisms of action. However, individuals are encouraged to consult doctors to determine if UDCA is appropriate for a given health condition. With expert guidance, UDCA may offer a natural way to support liver function, digestive health, and metabolic regulation.

 

Hongda Phytochemistry Co., Ltd. prides itself on offering a range of flexible services to meet the diverse needs of our clients. As a direct producer, we readily accommodate customized production and Packaging requests, ensuring that the final product aligns perfectly with your specific requirements. Additionally, we are pleased to provide free samples, allowing you to experience the quality of our offerings firsthand. Moreover, our newly established capsule production workshop enables us to tailor capsule products according to your unique specifications. We are also actively engaged in global Exhibitions, including but not limited to the European CPHI, European International Vitafoods, European Food Ingredients Exhibition FIE, Functional Food and Healthy Food Exhibition FFFI, and American SSE.

 

At Hongda Phytochemistry, we are dedicated to delivering excellence in every aspect of our operations. We specialize in providing high-quality UDCA Powder, and our professional team is readily available to address any inquiries you may have about this product or other related offerings. For further information, please feel free to consult our team at duke@hongdaherb.com.

 

References:

 

1、Bafutto, M., Almeida, J.R., Leite, N.V., Oliveira, E.C., Costa, M.A. Treatment of postcholecystectomy symptoms based on the hypothesis of neuromuscular dysfunction of the sphincter of Oddi: results of a pilot study. BMC Gastroenterol. 2013;13:172.

2、Beuers, U., Trauner, M., Jansen, P., Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62:S25-37.

3、Ferslew, B.C., Xie, G., Johnston, C.K., Su, M., Stewart, P.W., Jia, W., Brouwer, K.L.R. Altered Bile Composition Associated With Liver Injury in Mice Deficient of Mrp3 and Mrp4. Toxicol Sci. 2015 Jul;146(1):65-73.

4、Grambihler, A., Hintermann, E., Pfeilschifter, J., Köhn-Gaone, J., Freigang, S., Schaffner, F. Ursodeoxycholic acid inhibits liver disease cell growth via a COX-2 independent mechanism. Journal of Hepatology. 2012;57(6):1221-1229.

5、Khoruts, A., Stahnke, L., McClain, C.J., Sadowski, D., Mays, T. A randomized, double-blind, placebo-controlled trial of a conjugated bile acid (ursodeoxycholic Acid) in inflammatory bowel disease. Nutr Clin Pract. 2011;26(5):548-554.

6、Kowdley KV, Luketic V, Chapman R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018;67(5):1890‐1902.

7、Lajczak, N.K., Saint-Criq, V., Garat, J.M., Rolli-Derkinderen, M., Bourrier, T., Macone, A., Peranzoni, V., Langlois, A., van der Merwe, S., Chirico G., de la Ballina LR, Mayeur C, Ait-Belgnaoui A, Vinel JP, Joseph J, Peyrin-Biroulet L, Germain S, Oudart H, Bronowicki JP, Palazzo M, Gaulard P, Farinotti R, Wyart C, Vetrano S, Neunlist M, Gallois C, Housset C, Rainteau D, Paci P, Vaulont S, Leturque A, Humbert L, LeBorgne R, Cosnes J, Bevivino G, Robine S, Karrasch T, Pais de Barros JP, Bertolotti P, Colnot S, Lesuffleur T, Theret N, Perlemuter G. Ursodeoxycholic Acid Exerts Beneficial Effects in Experimental Colitis. Mol Ther. 2019;27(7):1295-1312.

8、Mazidi M, Ravipati P, Gao HK, Rezaie P, Pasdar A, Kengne AP. Effects of ursodeoxycholic acid on glycemic parameters: A meta-analysis. J Diabetes Metab Disord. 2018;17(2):277-286. Published 2018 Nov 1. doi:10.1007/s40200-018-0359-9

9、Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10(12):1352-8.

10、Shi, H., Medvedovic, M., Marrero, J.A., et al. Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Dig Dis Sci. 2017;62(11):3087-3095.

11、Tilburg, A.J., Levinthal, G.N., Nguyen, D.L., Grossman, R., Sulkowski, M.S., Falck-Ytter, Y., Brandt, L.J., Kochman, M.L., Ginsberg, G.G., McCashland, T.M., Murray, J.A., Schechner, R.S., Schwartz, J., Singh, V.K. Effects of oral ursodeoxycholic acid administration in refractory coeliac sprue patients: a pilot study. Aliment Pharmacol Ther. 2013;37(7):697-704.